Abstract
Introduction: This multicenter study aimed to determine whether the pretreatment prognostic nutrition index (PNI) or a change in the index after two treatment courses could be a biomarker for predicting treatment sensitivity in patients with unresectable advanced or recurrent gastric cancer treated using chemotherapy and nivolumab as the first-line treatment. Methods: This multicenter retrospective study with 104 patients was conducted at 12 institutions. PNI was calculated before treatment and after two courses of treatment in each case. We also focused on changes in PNI from the pretreatment value. Results: After two courses of chemotherapy plus nivolumab treatment, the high PNI group had significantly better rates of overall survival (OS) (p = 0.0016) and time-to-treatment failure (p = 0.0060). Low PNI was an independent prognostic factor predicting both therapeutic sensitivity to chemotherapy plus nivolumab treatment and poorer OS. Furthermore, correlation with low pretreatment PNI transitioning to high after two courses of treatment was not noted in any patient in the progressive disease group (p = 0.0075). Conclusions: PNI is a score composed of a patient’s albumin level and lymphocyte count that can be easily assessed in daily clinical practice. Evaluating it is easy for each treatment; thus, when there is a focus on its transition, PNI could be a very powerful biomarker for predicting treatment sensitivity.
Journal Section:
Clinical Study
References
1.
Sung
H
, Ferlay
J
, Siegel
RL
, Laversanne
M
, Soerjomataram
I
, Jemal
A
, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
. CA Cancer J Clin
. 2021
;71
(3
):209
–49
. 2.
Liu
D
, Lu
M
, Li
J
, Yang
Z
, Feng
Q
, Zhou
M
, et al. The patterns and timing of recurrence after curative resection for gastric cancer in China
. World J Surg Oncol
. 2016
;14
(1
):305
. 3.
Janjigian
YY
, Shitara
K
, Moehler
M
, Garrido
M
, Salman
P
, Shen
L
, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
. Lancet
. 2021
;398
(10294
):27
–40
. 4.
Kang
YK
, Chen
LT
, Ryu
MH
, Oh
DY
, Oh
SC
, Chung
HC
, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
. Lancet Oncol
. 2022
;23
(2
):234
–47
. 5.
Onodera
T
, Goseki
N
, Kosaki
G
. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients
. Nihon Geka Gakkai Zasshi
. 1984
;85
(9
):1001
–5
.6.
Migita
K
, Matsumoto
S
, Wakatsuki
K
, Ito
M
, Kunishige
T
, Nakade
H
, et al. A decrease in the prognostic nutritional index is associated with a worse long-term outcome in gastric cancer patients undergoing neoadjuvant chemotherapy
. Surg Today
. 2017
;47
(8
):1018
–26
. 7.
Korkmaz
M
, Eryılmaz
MK
, Er
MM
, Koçak
MZ
, Demirkıran
A
, Karaağaç
M
, et al. Is the prognostic nutritional index a prognostic marker for the survival of patients with lymph-node positive Stage II–III gastric cancer who receive adjuvant chemotherapy
. J Gastrointest Cancer
. 2023
;54
(3
):962
–9
. 8.
Xiao
H
, Zhou
H
, Zhang
P
, Xiao
H
, Liu
K
, Chen
X
, et al. Association among the prognostic nutritional index, completion of adjuvant chemotherapy, and cancer-specific survival after curative resection of stage II/III gastric cancer
. Eur J Clin Nutr
. 2020
;74
(4
):555
–64
. 9.
Okubo
K
, Arigami
T
, Matsushita
D
, Tanaka
T
, Tsuruda
Y
, Noda
M
, et al. Clinical impact of the prognostic nutritional index as a predictor of outcomes in patients with Stage II/III gastric cancer: a retrospective cohort study
. Oncology
. 2021
;99
(6
):380
–8
. 10.
Pan
Y
, Ma
Y
, Dai
G
. The prognostic value of the prognostic nutritional index in patients with advanced or metastatic gastric cancer treated with immunotherapy
. Nutrients
. 2023
;15
(19
):4290
. 11.
Zhang
L
, Ma
W
, Qiu
Z
, Kuang
T
, Wang
K
, Hu
B
, et al. Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors
. Front Immunol
. 2023
;14
:1219929
. 12.
Eisenhauer
EA
, Therasse
P
, Bogaerts
J
, Schwartz
LH
, Sargent
D
, Ford
R
, et al. New response evaluation criteria in solid tumours: revised RECIST guideline. version 1.1
. Eur J Cancer
. 2009
;45
(2
):228
–47
. 13.
Mantovani
A
, Allavena
P
, Sica
A
, Balkwill
F
. Cancer-related inflammation
. Nature
. 2008
;454
(7203
):436
–44
. 14.
Galdiero
MR
, Garlanda
C
, Jaillon
S
, Marone
G
, Mantovani
A
. Tumor associated macrophages and neutrophils in tumor progression
. J Cell Physiol
. 2013
;228
(7
):1404
–12
. 15.
Cross
CE
, van der Vliet
A
, O’Neill
CA
, Louie
S
, Halliwell
B
. Oxidants, antioxidants, and respiratory tract lining fluids
. Environ Health Perspect
. 1994
;102
(Suppl 10
):185
–91
. 16.
Roche
M
, Rondeau
P
, Singh
NR
, Tarnus
E
, Bourdon
E
. The antioxidant properties of serum albumin
. FEBS Lett
. 2008
;582
(13
):1783
–7
. 17.
Fleck
A
, Raines
G
, Hawker
F
, Trotter
J
, Wallace
PI
, Ledingham
IM
, et al. Increased vascular permeability: a major cause of hypoalbuminaemia in disease and injury
. Lancet
. 1985
;1
(8432
):781
–4
. 18.
Dunn
GP
, Old
LJ
, Schreiber
RD
. The immunobiology of cancer immunosurveillance and immunoediting
. Immunity
. 2004
;21
(2
):137
–48
. 19.
Kitayama
J
, Yasuda
K
, Kawai
K
, Sunami
E
, Nagawa
H
. Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer
. Radiat Oncol
. 2010
;5
:47
. 20.
Sasaki
T
, Nishiwada
S
, Nakagawa
K
, Nagai
M
, Terai
T
, Hokuto
D
, et al. Integrative analysis identifies activated anti-tumor immune microenvironment in lung metastasis of pancreatic cancer
. Int J Clin Oncol
. 2022
;27
(5
):948
–57
. 21.
Tumeh
PC
, Harview
CL
, Yearley
JH
, Shintaku
IP
, Taylor
EJM
, Robert
L
, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance
. Nature
. 2014
;515
(7528
):568
–71
. 22.
Zou
W
, Wolchok
JD
, Chen
L
. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations
. Sci Transl Med
. 2016
;8
(328
):328rv4
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
